ab209421 is the carrier-free version of ab168381 This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with

Ab209421 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

Maxpar® is a trademark of Fluidigm Canada Inc.

Alpha-synuclein was the first gene to be linked to Parkinson’s disease (PD) and remains the most promising link to PD pathogenesis, where there is genetic evidence that it may play a causal role. In the brain, alpha-synuclein is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.
Recent studies also indicate that alpha-synuclein undergoes post-translational modification. Though the role of many of these modifications is still under investigation, phosphorylation at Serine 129 may affect alpha-synuclein aggregations and may also serve as marker of disease pathogenesis. With the advent of this phospho-specific Serine 129 antibody, The Michael J. Fox Foundation hopes to ensure that the putative role of this modification can be further examined by all researchers.

Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.